A randomized, double blind, placebo-controlled, three arm, parallel group, multicenter, multinational safety and efficacy trial of 300 mg and 900 mg of abetimus sodium in systemic lupus erythematosus (sle) patients with a history of renal disease.

Trial Profile

A randomized, double blind, placebo-controlled, three arm, parallel group, multicenter, multinational safety and efficacy trial of 300 mg and 900 mg of abetimus sodium in systemic lupus erythematosus (sle) patients with a history of renal disease.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Abetimus (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 03 Oct 2013 Status changed from recruiting to discontinued as reported by Sri Lanka Clinical Trials Registry.
    • 17 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top